{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:07:11Z","timestamp":1779232031694,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtocrr.2026.100989","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:04:48Z","timestamp":1773677088000},"page":"100989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Yttrium-90 Radioembolization Versus Transarterial Embolization for Lung Carcinoid Hepatic Metastasis"],"prefix":"10.1016","volume":"7","author":[{"given":"Gavin","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios Platon","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena N.","family":"Petre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etay","family":"Ziv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos T.","family":"Sofocleous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlasios","family":"Sotirchos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian Gonzalez","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica S.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.100989_bib1","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","article-title":"Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids","volume":"26","author":"Caplin","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jtho.2019.02.002","article-title":"Characterization, prognosis, and treatment of patients with metastatic lung carcinoid tumors","volume":"14","author":"Robelin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib3","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.3747\/co.25.3808","article-title":"Advanced typical and atypical carcinoid tumours of the lung: management recommendations","volume":"25","author":"Melosky","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cllc.2020.12.004","article-title":"Recent advances in the management of typical and atypical lung carcinoids","volume":"22","author":"Prinzi","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2026.100989_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jamcollsurg.2019.12.026","article-title":"Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis","volume":"230","author":"Egger","year":"2020","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jtocrr.2026.100989_bib7","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2026.100989_bib8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/modpathol.2012.53","article-title":"Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors","volume":"25","author":"de Wilde","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jvir.2023.10.025","article-title":"Yttrium-90 transarterial radioembolization of primary lung cancer metastases to the liver","volume":"35","author":"Alexander","year":"2024","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib10","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.3390\/cancers15215202","article-title":"Hepatic hilar block as an adjunct to transarterial embolization of neuroendocrine tumors: a retrospective review of safety and efficacy","volume":"15","author":"Jain","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2026.100989_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2026.100989_bib13","series-title":"Lung carcinoid tumors","author":"Limaiem","year":"2024"},{"key":"10.1016\/j.jtocrr.2026.100989_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12902-020-0525-6","article-title":"Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014","volume":"20","author":"Trikalinos","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.jtocrr.2026.100989_bib15","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib16","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2293::AID-CNCR8>3.0.CO;2-E","article-title":"Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors","volume":"83","author":"Eriksson","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2026.100989_bib17","first-page":"335","article-title":"Prognostic factors in typical and atypical pulmonary carcinoids","volume":"17","author":"Ramirez","year":"2017","journal-title":"Ochsner J"},{"key":"10.1016\/j.jtocrr.2026.100989_bib18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1510\/icvts.2007.173328","article-title":"Typical and atypical pulmonary carcinoids: our institutional experience","volume":"7","author":"Bini","year":"2008","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.jtocrr.2026.100989_bib19","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/00000478-199808000-00003","article-title":"Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid","volume":"22","author":"Travis","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib20","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/cancers15082249","article-title":"Neuroendocrine tumors: genomics and molecular biomarkers with a focus on metastatic disease","volume":"15","author":"Alexander","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2026.100989_bib21","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1007\/s00270-022-03209-9","article-title":"Analysis of tumor burden as a biomarker for patient survival with neuroendocrine tumor liver metastases undergoing intra-arterial therapies: a single-center retrospective analysis","volume":"45","author":"Miszczuk","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib22","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3390\/cancers16030502","article-title":"Prognostic thresholds of mitotic count and Ki-67 labeling index for recurrence and survival in lung atypical carcinoids","volume":"16","author":"Soldath","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2026.100989_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.669484","article-title":"Outcome of patients with metastatic lung neuroendocrine tumors submitted to first line monotherapy with somatostatin analogs","volume":"12","author":"Lenotti","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jtocrr.2026.100989_bib24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3892\/mco.2014.332","article-title":"Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: results from the large database of a multidisciplinary group clinical multicenter study","volume":"2","author":"O'Connor","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/MPA.0b013e3181f94cc4","article-title":"Comparison of functional and nonfunctional neuroendocrine tumors in the pancreas and peripancreatic region","volume":"40","author":"Wang","year":"2011","journal-title":"Pancreas"},{"key":"10.1016\/j.jtocrr.2026.100989_bib26","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40618-022-01956-7","article-title":"Development and validation of a survival prediction model and risk stratification for pancreatic neuroendocrine neoplasms","volume":"46","author":"Lu","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jtocrr.2026.100989_bib27","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2026.100989_bib28","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.31192","article-title":"Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases","volume":"124","author":"Kim","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2026.100989_bib29","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0959-8049(01)00073-9","article-title":"Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours","volume":"37","author":"Aparicio","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2026.100989_bib30","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1111\/j.1572-0241.2000.03210.x","article-title":"The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors","volume":"95","author":"Ducreux","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2016.11.034","article-title":"Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids","volume":"75","author":"Sullivan","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2026.100989_bib32","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jvir.2013.01.034","article-title":"Metastatic NET to the liver: treatment with bland embolization versus radioembolization","volume":"24","author":"Gebhard","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib33","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jvir.2019.06.003","article-title":"Radioembolization-induced chronic hepatotoxicity: a single-center cohort analysis","volume":"30","author":"Currie","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12885-022-09302-z","article-title":"Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry","volume":"22","author":"Wong","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtocrr.2026.100989_bib35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/0168-8278(95)80103-0","article-title":"Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever","volume":"22","author":"Castells","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib36","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10157-019-01751-4","article-title":"Incidence and risk factors of contrast-induced nephropathy after transcatheter arterial chemoembolization in hepatocellular carcinoma","volume":"23","author":"Aoe","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.jtocrr.2026.100989_bib37","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017393","article-title":"Polymicrobial bacteremia after treatment of transcatheter arterial chemoembolization: a case report","volume":"98","author":"Fang","year":"2019","journal-title":"Medicine (Baltimore)"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:48:20Z","timestamp":1779230900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666364326000408"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.100989","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yttrium-90 Radioembolization Versus Transarterial Embolization for Lung Carcinoid Hepatic Metastasis","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.100989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100989"}}